Castle Biosciences (CSTL) Shares Outstanding (Weighted Average) (2018 - 2026)

Castle Biosciences has disclosed Shares Outstanding (Weighted Average) across 9 years of filings, most recently posting $29.9 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $29.9 million, up 4.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.9 million (up 4.47% YoY), and the FY2025 annual result was $29.0 million, up 4.36% from the prior year.
• Shares Outstanding (Weighted Average) came in at $29.9 million for Q1 2026 at Castle Biosciences, up from $29.0 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $29.9 million in Q1 2026 to a low of $25.4 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $27.5 million (2024), against an average of $27.4 million.
• Across the five-year window, Shares Outstanding (Weighted Average) rose 1.97% in 2023 and advanced 5.11% in 2025, its largest moves.
• Castle Biosciences' Shares Outstanding (Weighted Average) stood at $26.1 million in 2022, then grew by 2.87% to $26.8 million in 2023, then increased by 3.63% to $27.8 million in 2024, then grew by 4.36% to $29.0 million in 2025, then rose by 3.12% to $29.9 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $29.9 million (Q1 2026), $29.0 million (Q4 2025), and $29.1 million (Q3 2025), per Business Quant data.